共 50 条
- [31] Use of sodium-glucose co-transporter-2 inhibitors in Asian patients with type 2 diabetes and kidney disease: An Asian perspective and expert recommendations DIABETES OBESITY & METABOLISM, 2021, 23 (02): : 299 - 317
- [34] Sotagliflozin, a dual sodium-glucose co-transporter-1 and sodium-glucose co-transporter-2 inhibitor, reduces the risk of cardiovascular and kidney disease, as assessed by the Steno T1 Risk Engine in adults with type 1 diabetes DIABETES OBESITY & METABOLISM, 2023, 25 (07): : 1874 - 1882
- [35] Changes in serum potassium in people with type 2 diabetes taking sodium-glucose co-transporter-2 inhibitors PHARMACOTHERAPY, 2025,
- [36] The Impact of Sodium-Glucose Co-Transporter-2 Inhibition on Insulin Resistance and Inflammation in Patients with Type 2 Diabetes: A Retrospective Study MEDICINA-LITHUANIA, 2025, 61 (02):
- [38] Sodium-glucose co-transporter-2 inhibitor use and risk of lower-extremity amputation: Evolving questions, evolving answers DIABETES OBESITY & METABOLISM, 2019, 21 (05): : 1223 - 1236